ALRN - Aileron Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
11.96M
Enterprise Value 3
-14.25M
Trailing P/E
N/A
Forward P/E 1
-0.50
PEG Ratio (5 yr expected) 1
-0.20
Price/Sales (ttm)
N/A
Price/Book (mrq)
0.40
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
0.51

Trading Information

Stock Price History

Beta (3Y Monthly) 2.27
52-Week Change 3-81.65%
S&P500 52-Week Change 37.98%
52 Week High 33.0990
52 Week Low 30.4250
50-Day Moving Average 30.7441
200-Day Moving Average 30.9781

Share Statistics

Avg Vol (3 month) 3364.09k
Avg Vol (10 day) 3380.43k
Shares Outstanding 527.81M
Float 16.88M
% Held by Insiders 177.03%
% Held by Institutions 143.57%
Shares Short (Sep 30, 2019) 4161.7k
Short Ratio (Sep 30, 2019) 40.43
Short % of Float (Sep 30, 2019) 40.82%
Short % of Shares Outstanding (Sep 30, 2019) 40.58%
Shares Short (prior month Aug 30, 2019) 4257.82k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-42.40%
Return on Equity (ttm)-91.81%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-18.45M
EBITDA -27.88M
Net Income Avi to Common (ttm)-28.85M
Diluted EPS (ttm)-1.6050
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)31.52M
Total Cash Per Share (mrq)1.13
Total Debt (mrq)5.23M
Total Debt/Equity (mrq)17.44
Current Ratio (mrq)6.04
Book Value Per Share (mrq)1.08

Cash Flow Statement

Operating Cash Flow (ttm)-26.73M
Levered Free Cash Flow (ttm)-20.5M